This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in newly diagnosed and recurrent CD70+ Pediatric High-Grade Gliomas (pHGG) and Diffuse Intrinsic Pontine Glioma (ndDIPG)
Newly diagnosed high-grade glioma (WHO Grade III or IV)
Newly diagnosed DIPG (after first 2 HGG patients are treated)
Recurrent or progressive high-grade glioma
Age 4-18 years old for ndHGG. Age 4-30 for rHGG. Age 4-30 for nd DIPG.
Patients with primary spinal cord tumors ARE eligible.
CD70 positive (≥5%, 1+) The tumors from the surgical resection by immunohistochemistry will be confirmed by validated assay performed at UF Health Pathology, CLIA certified Lab.
= Low level
= Moderate level
University of Florida
Lead sponsor
Florida Department of Health, Live Like Bella
Collaborator
St. Baldrick's Foundation
Collaborator
American Brain Tumor Association
Collaborator